ReNeuron stem cell trial clears first hurdle

An independent data safety monitoring board has signed off on the initial use of ReNeuron's stem cell therapy for stroke, clearing the way for more testing and fueling a jump in the company's share price. "We are delighted that the PISCES stroke clinical trial will now move forward to the next milestone, being the treatment of the remainder of the first patient cohort," said CEO Michael Hunt. "It is both encouraging and reassuring to hear that no safety issues have been observed with the first patient treated with ReN001 and again, we wish him and his family well." Report